Molecular Recognition in the HIV-1 Capsid/Cyclophilin
A Complex
Sanghee Yoo1
, David G. Myszka2
, Chin-yah Yeh1
, Maureen McMurray1
Christopher P. Hill1 and Wesley I. Sundquist
1
*
1
Departments of Biochemistry
2
Oncological Sciences
University of Utah, Salt Lake
City, UT 84132, USA
The HIV-1 capsid protein (CA) makes an essential interaction with the
human peptidyl prolyl isomerase, cyclophilin A (CypA), that results in
packaging of CypA into the virion at a CA to CypA stoichiometry of
10:1. The 231 amino acid residue capsid protein is composed of an
amino-terminal CypA binding domain (1 to 151; CA151) and a carboxylï¿¾terminal dimerization domain (151 to 231). We Â®nd that CypA binds
dimeric CA and monomeric CA151 with identical intrinsic afÂ®nities
(Kd Âˆ 16(4) mM). This result demonstrates that capsid dimerization and
cyclophilin A binding are not thermodynamically coupled and suggests
that the substoichiometric ratio of CypA in the HIV-1 virion results from
the intrinsic stability of the CA/CypA complex. In the known co-crystal
structure of the CA151/CypA complex, CypA binding is mediated excluï¿¾sively by an exposed capsid loop that spans residues Pro85 to Pro93. The
energetic contributions to CypA binding were quantiÂ®ed for each residue
in this loop, and the results demonstrate that the Gly89-Pro90 dipeptide
is the primary cyclophilin A recognition motif, with Pro85, Val86, His87,
Ala88, and Pro93 also making energetically favorable contacts. These stuï¿¾dies reveal that the active site of CypA, which can catalyze the isomerizaï¿¾tion of proline residues in vitro, also functions as a sequence-speciÂ®c,
protein-binding motif in HIV-1 replication.
# 1997 Academic Press Limited
Keywords: human immunodeÂ®ciency virus; capsid; cyclophilin; binding;
*Corresponding author chaperone
Introduction
The HIV-1 Gag polyprotein dictates both viral
assembly and the packaging of essential factors
into the virion (for reviews, see Wills &
Craven, 1991; Gelderblom et al., 1992; Hunter,
1994; KraÃˆusslich, 1996). It is now known that at
least one of these essential packaged factors is a
cellular protein, the abundant cytoplasmic proï¿¾line isomerase, cyclophilin A (CypA: Luban et al.,
1993; Franke et al., 1994b; Thali et al., 1994).
CypA binds to the central ``capsid'' domain of
Gag and is thereby packaged at a virion stoiï¿¾chiometry of 2000 CA:  200 CypA (Franke
et al., 1994b; Thali et al., 1994; Franke & Luban,
1995; Ott et al., 1995). As the immature virion
buds, the 55 kDa Gag polyprotein (residues 1 to
499) is cleaved by the viral protease to produce
three new proteins, matrix (MA, residues 1 to
132), capsid (CA, 133 to 363) and nucleocapsid
(NC, 378 to 432), as well as three smaller polyï¿¾peptides (p6, p2 and p1: Di Marzo Veronese
et al., 1988; Henderson et al., 1992). Following
cleavage, the capsid protein rearranges into the
characteristic cone-shaped core structure that
surrounds the RNA genome at the center of the
virion. CypA then appears to exert its essential
function on capsid immediately following the
infection of a new cell, possibly helping to disï¿¾assemble the capsid core structure (Braaten et al.,
1996a,c; Gamble et al., 1996).
Cyclophilin A is the founding member of what
is now a large family of proteins that are ubiquiï¿¾tous in both prokaryotes and eukaryotes
(Handschumacher et al., 1984; Fischer et al., 1989;
Takahashi et al., 1989; Schreiber & Crabtree, 1992;
sundquist@medschool.med.utah.edu
Abbreviations used: CA, MA and NC HIV-1 capsid,
matrix and nucleocapsid proteins; Cyp, cyclophilin; Rh,
rhodopsin; ITC, isothermal titration microcalorimetry;
SPR, surface plasmon resonance; GST, glutathione-Sï¿¾transferase; NHS, N-hydroxysuccinimide; EDC, N-ethylï¿¾N0
-(3-diethylaminopropyl)carbodiimide; RU, response
units.
J. Mol. Biol. (1997) 269, 780Â±795
0022Â±2836/97/250780Â±16 $25.00/0/mb971051 # 1997 Academic Press LimitedStamnes et al., 1992; Walsh et al., 1992; Kunz &
Hall, 1993). CypA is an abundant cytoplasmic proï¿¾tein, but other cyclophilin family members exhibit
tissue-speciÂ®c and organelle-speciÂ®c expression
patterns, and function as subdomains of larger proï¿¾teins. Various cyclophilin family members have
been reported to play roles in such diverse and imï¿¾portant cellular functions as the heat-shock reï¿¾sponse (Sykes et al., 1993), cell-surface recognition
(Anderson et al., 1993; Friedman et al., 1993), proï¿¾tein folding and trafÂ®cking (Colley et al., 1991;
Lodish & Kong, 1991; Helekar et al., 1994; Ferreira
et al., 1996), lactate metabolism (Davis et al., 1992),
and various intracellular signaling pathways (Xu
et al., 1992; Ratajczak et al., 1993; Bram & Crabtree,
1994; Cardenas et al., 1994; Chang & Lindquist,
1994; Duina et al., 1996; Freeman et al., 1996;
Weisman et al., 1996).
Despite extensive study, it is not yet clear preï¿¾cisely what cyclophilins do in the cell. The broad
spectrum of biological pathways in which they
appear suggests a role for cyclophilins in protein
folding and, indeed, two distinct roles for cyclophiï¿¾lins in the folding process have been proposed.
First, the rotamase activity of cyclophilins may
allow them to play a general role in accelerating
protein folding. Proline isomerization is the rateï¿¾limiting step for the folding of many proteins
in vitro (e.g. see Brandts et al., 1975; Schmid &
Baldwin, 1978; Jackson & Ferscht, 1991; Schmid,
1993) and CypA accelerates the overall folding
rates of a number of such proteins (reviewed by
Schmid, 1993). A second role for cyclophilins in
protein folding is suggested by the fact that CypA
can act as a molecular chaperone in vitro, increasï¿¾ing the yield of correctly folded protein by supï¿¾pressing off-pathway folding reactions and
preventing the aggregation of proteins in their unï¿¾folded states (FreskgaÃŠrd et al., 1992; Lilie et al.,
1993; Freeman et al., 1996). Intriguingly, this chaï¿¾perone activity appears independent of the enzyï¿¾me's rotamase activity. Although the rotamase and
chaperone activities of cyclophilins have been well
documented in vitro, the roles of these two activiï¿¾ties in vivo are not fully understood.
A second major unanswered question in cycloï¿¾philin biology is whether or not cyclophilins typiï¿¾cally bind speciÂ®cally to their target proteins. On
the one hand, if cyclophilins normally function as
general prolyl isomerases, they might be expected
to exhibit little sequence speciÂ®city. This model is
consistent with the reported lack of CypA subï¿¾strate discrimination across a series of different
proline-containing model peptide sequences
(Harrison & Stein, 1990). However, at least a subset
of cyclophilins seem to bind speciÂ®cally to target
proteins in order to perform their essential funcï¿¾tions. The best-characterized example of this is
NinaA, a cyclophilin of the Drosophila eye, which
forms a speciÂ®c complex with rhodopsin 1 (Rh1:
Schneuwly et al., 1989; Shieh et al., 1989; Baker et al.,
1994). NinaA is essential for translocation of Rh1
from the endoplasmic reticulum, through the
secretory pathway, and into the rhabdomere where
phototransduction occurs (Colley et al., 1991).
Although the Rh1/NinaA interaction is not underï¿¾stood in detail, loss of function mutations cluster
about the ninaA active site, suggesting that the
active site mediates Rh1 binding (Ondek et al.,
1992). Other examples in which cyclophilins apï¿¾pear to form speciÂ®c complexes with their target
proteins include CypB binding to the calcium-sigï¿¾naling protein CAML (Bram & Crabtree, 1994),
and CypC binding to the cell-surface protein
CyCAP (Friedman et al., 1993). It therefore appears
that sequence-speciÂ®c protein binding may prove a
recurring theme in cyclophilin function.
In addition to its importance in HIV-1 replicaï¿¾tion, the HIV-1 CA/CypA interaction may serve as
a paradigm for understanding how cyclophilins
achieve sequence-speciÂ®c protein binding. Like
NinaA, the CypA active site appears to participate
in capsid binding, since CA/CypA complex forï¿¾mation is competitively inhibited by the rotamase
inhibitor cyclosporine and its analogues (Luban
et al., 1993; Franke et al., 1994b; Thali et al., 1994;
Billich et al., 1995). Moreover, mutation of a single
capsid proline residue, Pro90, abolishes CypA
binding, packaging, and viral replication (Franke
et al., 1994 b). In principle, however, binding speci-
Â®city in the CA/CypA complex could either be
achieved entirely within the CypA binding site or
through additional protein-protein interactions that
extend beyond the active site. The latter model is
supported by the report that high-afÂ®nity cyclophiï¿¾lin A binding requires dimerization of the target
Gag (or capsid) protein (Colgan et al., 1996). This
observation suggests either that capsid dimerizaï¿¾tion creates a high-afÂ®nity cyclophilin A binding
surface or that distal CypA-CypA interactions
allow CypA to bind cooperatively to the capsid
dimer.
Several recent experiments suggest an alternative
model, however, in which the CypA active site itï¿¾self discriminates between proline residues emï¿¾bedded in different local sequence contexts. For
example, Luban and co-workers have shown that
HIV-1 CA residue Gly89, as well as Pro90, is essenï¿¾tial for CypA binding and viral packaging (Braaten
et al., 1996b). Similarly, our recent CA151/CypA
co-crystal structure revealed that capsid residues
85 to 93 make a series of favorable contacts in the
CypA active site, with no other signiÂ®cant CypAï¿¾CA or CypA-CypA interaction (Gamble et al.,
1996).
In order to determine precisely how cyclophilin
A recognizes the HIV-1 capsid protein, we have
examined various aspects of CA/CypA complex
formation in solution. These experiments reveal the
thermodynamics and energetic determinants of cyï¿¾clophilin A binding, and demonstrate that the cyï¿¾clophilin A active site itself acts as a sequenceï¿¾speciÂ®c, protein-binding motif.
HIV-1 Capsid/Cyclophilin A Interaction 781Results
Recombinant capsid proteins
Primary sequences and labeling schemes for the
HIV-1 capsid and human cyclophilin A proteins
are shown in Figure 1(a) and (b), respectively. The
crystallographically deÂ®ned interaction between
cyclophilin A and the amino-terminal domain of
the capsid is shown in Figure 1(c) (Gamble et al.,
1996). As shown in Figure 2, efÂ®cient systems have
been developed for expressing and purifying large
quantities of the full-length HIV-1 capsid protein
(CA; Figure 2(a)), the amino-terminal capsid doï¿¾main (CA151; Figure 2(b)), and human cyclophilin
A (CypA; Figure 2(c)). Both capsid proteins are
ideally suited for biophysical and structural stuï¿¾dies, since they are highly soluble (>50 mg/ml)
and can be efÂ®ciently isolated in high yields
(>30 mg/l Escherichia coli culture).
Self-association of capsid proteins
Several groups have reported that HIV-1 capsid
proteins dimerize in vitro (Ehrlich et al., 1992, 1994;
RoseÃ‚ et al., 1992; Brooks et al., 1994). Our full-length
Figure 1. (a) Primary sequence, numbering schemes,
and known secondary structure of HIV-1NL4-3 capsid
proteins used in this study. The secondary structure of
CA151 (Gamble et al., 1996; Gitti et al., 1996; Momany
et al., 1996) and the cyclophilin A binding site (denoted
CypA), are shown below the primary sequence of the
intact capsid protein (CA). Cylinders denote helical
regions, arrows denote beta strands, and broken lines
denote regions of the structures that are disordered in
the existing structures. (b) Primary sequence and secï¿¾ondary structure of human cyclophilin A. The secondary
structure of the CypA protein (Ke et al., 1991) is shown
above the primary sequence. Residues involved in capï¿¾sid binding are underlined (Gamble et al., 1996). (c) Ribï¿¾bon representation of the CA151/CypA complex.
Figure 2. Protein expression and puriÂ®cation. (a) SDSï¿¾PAGE analysis of the expression and puriÂ®cation of the
intact HIV-1 capsid protein (CA). Lane 1, total cellular
BL21 (DE3) E. coli proteins prior to induced expression
of the capsid protein; lane 2, total cellular BL21 (DE3)
E. coli proteins following induction of HIV-1 capsid proï¿¾tein; lane 3, puriÂ®ed HIV-1 capsid protein. (b) SDSï¿¾PAGE analysis of the expression and puriÂ®cation of the
truncated HIV-1 capsid protein (CA151). Lane 1, total celï¿¾lular BL21 (DE3) E. coli proteins prior to induced exï¿¾pression of CA151; lane 2, total cellular BL21 (DE3) E. coli
proteins following induction of CA151; lane 3, puriÂ®ed
CA151 protein. (c) SDS-PAGE analysis of the expression
and puriÂ®cation of human cyclophilin A (CypA). Lane
1, total cellular BL21 (DE3) E. coli proteins prior to
induced expression of CypA; lane 2, total cellular BL21
(DE3) E. coli proteins following induction of CypA; lane
3, puriÂ®ed CypA protein.
782 HIV-1 Capsid/Cyclophilin A Interactionrecombinant capsid protein (25.6 kDa) is also preï¿¾dominantly dimeric at a concentration of 200 mM
as analyzed by dynamic light-scattering
(Mest Âˆ 51(2) kDa). The CA monomer-dimer equiï¿¾librium was quantiÂ®ed by analytical ultracentrifuï¿¾gation, yielding an estimated dissociation constant
of 18(1) mM (Figure 3(a)). This value agrees well
with previous measurements of the capsid Kd,
which ranged between 10 and 30 mM (RoseÃ‚ et al.,
1992; Brooks et al., 1994).
In order to test the inÂ¯uence of capsid dimerizaï¿¾tion on cyclophilin A binding, it was necessary to
create a monomeric capsid protein. Partial proteolï¿¾ysis and NMR structural studies have indicated
that capsid residues 1 to 151 (CA151) form an indeï¿¾pendently folded domain that is monomeric at low
millimolar concentrations (Gitti et al., 1996). This
observation was conÂ®rmed by equilibrium sediï¿¾mentation and dynamic light-scattering analyses of
CA151. Sedimentation distributions of three differï¿¾ent CA151 concentrations were globally Â®t to a
simple monomer model (Figure 3(b)), yielding a
shape-independent estimated particle mass of
16.4(0.3) kDa, in agreement with the calculated
mass of the CA151 monomer (16.7 kDa). Similarly,
CA151 appeared monomeric as measured by dyï¿¾namic light-scattering (Mest Âˆ 18.1(0.1) kDa;
158 mM).
Calorimetric quantification of the capsid/
cyclophilin A interaction
Isothermal titration microcalorimetry (ITC) was
used to measure dissociation constants for the CA/
CypA and CA151/CypA complexes. This method
has the advantage of allowing rigorous quantiÂ®-
cation of the stoichiometry, energy and enthalpy of
complex formation in solution, but requires multiï¿¾milligram quantities of pure proteins (Brandts et al.,
1990; Bundle & Sigurskjold, 1994; Fisher & Singh,
1995). The titration of CA151 into cyclophilin A is
shown in Figure 4(a). Raw calorimetric data were
corrected by subtraction of the appropriate blank
titrations (negligible), and the integrated binding
isotherm (Figure 4(b)) was successfully Â®t to a
single-site binding model, yielding a CA151 to
CypA binding ratio of 1.13(0.05), Kd Âˆ 16(4)
mM, and H Âˆ Ã¿ 9.5(0.6) kcal/mol.
The analogous titration of cyclophilin A into
full-length capsid protein (CA) is shown in
Figure 4(c). Raw titration data were again corï¿¾rected by subtracting the appropriate blank
titrations. In this case the blank titration of
buffer into capsid resulted in signiÂ®cant heat abï¿¾sorbance, presumably owing to dissociation of
dimeric CA upon dilution. Nevertheless, the corï¿¾rected binding isotherm (Figure 4(d)) again Â®t a
single-site binding model, yielding a CypA to CA
stoichiometry of 1.01(0.04), Kd Âˆ 16(3) mM, and
H Âˆ Ã¿ 9.5(0.6) kcal/mol. These experiments deï¿¾Figure 3. Equilibrium sedimentation analyses of the oliï¿¾gomeric states of HIV-1 CA and CA151. (a) CA exhibits
a monomer-dimer equilibrium. The Figure shows raw
sedimentation data, the optimized global Â®t, and reï¿¾siduals (above) for sedimentation of a 9.8 mM sample of
CA. The global Â®t was performed using equilibrium
sedimentation data from initial protein concentrations of
5.6, 9.8 and 15.8 mM, yielding an estimated dissociation
constant, Kd Âˆ 1.8(0.1)  10Ã¿5 M. The reported error is
the 95% conÂ®dence level, the goodness of Â®t (GOF) was
1.67, and the Â®t exhibited small, random residuals.
(b) CA151 is monomeric. The Figure shows the raw sediï¿¾mentation data, optimized global Â®t, and residuals
(above) for a 14.9 mM sample of CA151. The estimated
protein mass is 16.4(0.3) kDa, in good agreement with
the mass of the CA151 monomer (16.7 kDa). The global
Â®t was performed using equilibrium sedimentation data
from initial protein concentrations of 7.2, 14.9 and
34.3 mM. The GOF is 1.46 and the Â®t exhibited small,
random residuals.
Figure 4. Isothermal titration microcalorimetric analyses
of the cyclophilin A/capsid interaction. (a) Titration of
CA151 into CypA. Heat released at 20C when
632 mM CA151 was titrated in 20 ml aliquots into
1.296 ml 59 mM CypA. (b) Integrated binding isotherm
of the CA151/CypA titration and experimental Â®t to a
single-site model. The best Â®t (shown) yielded parï¿¾ameters of n Âˆ 1.13(0.05), Kd Âˆ 1.6(0.4)  10Ã¿5 MÃ¿1
,
H Âˆ Ã¿ 9.5(0.6) kcal/mol, w2 Âˆ9.0. (c) Titration of
CypA into CA. The titration was as described for (a)
except that 661 mM CypA was titrated into 59 mM CA.
(d) Integrated binding isotherm of the CA/CypA tiï¿¾tration and experimental Â®t to a single-site model. The
best Â®t (shown) yielded parameters of n Âˆ 1.01(0.04),
Kd Âˆ 1.6(0.3)  10Ã¿5 MÃ¿1
, H Âˆ Ã¿ 9.5(0.6) kcal/mol,
w2 Âˆ 7.1.
HIV-1 Capsid/Cyclophilin A Interaction 783   monstrate that capsid dimerization and CypA
binding are not coupled equilibria, since the
measured stoichiometry, equilibrium binding conï¿¾stants and enthalpies for CypA binding to CA151
and CA are indistinguishable, even though the
CA/CypA titration was performed at an initial
capsid concentration of 59 mM, where >50% of the
CA molecules were dimeric.
Surface plasmon resonance measurement of
the CA/CypA affinity
The large quantities of pure proteins required for
ITC measurements made this method impractical
for a comprehensive mutational analysis of the
CA/CypA interaction. Surface plasmon resonance
(SPR) spectroscopic methods were therefore also
used to quantify the interaction. SPR has distinct
advantages over ITC in speed, sensitivity and
scale, but requires independent validation to enï¿¾sure that binding equilibria are not altered by surï¿¾face effects (JoÃˆnsson et al., 1991; Malmqvist, 1993;
Morton et al., 1995; O'Shannessy & Winzor, 1996).
Initial experiments examined the binding of pure,
monomeric CA151 to a pure, immobilized glutaï¿¾thione-S-transferase-CypA fusion protein (GSTï¿¾CypA). GST-CypA was captured on the sensor surï¿¾face by an anti-GST antibody covalently linked to
the carboxymethyl dextran layer (JoÃˆnsson et al.,
1991), providing a homogeneous surface of unperï¿¾turbed CypA binding sites. CA151 binding was
then quantiÂ®ed by changes in the surface refractive
index. A correction for refractive index changes
due to bulk solvent and non-speciÂ®c background
binding was performed simultaneously in a separï¿¾ate Â¯ow-cell derivatized with the anti-GST antiï¿¾body binding to GST alone.
As shown in Figure 5(a), binding responses were
highly reproducible in repeated measurements
across a concentration range of 0 to 57 mM CA151.
The sensorgrams revealed that equilibrium was
achieved rapidly. Furthermore, the binding reï¿¾sponses returned to baseline levels very quickly
after washing with buffer, indicating that the comï¿¾plex has a very high dissociation rate. The magniï¿¾tudes of equilibrium binding responses at different
CA151 concentrations were used to determine the
dissociation constant for CA151/CypA complex by
non-linear least-squares Â®tting to a simple one-toï¿¾one interaction model. Equivalent dissociation conï¿¾stants were obtained for measurements made at
two different CypA surface derivatization levels
and the data from the two surfaces were averaged
to give the normalized binding data shown in
Figure 5(c). The Â®t provides an estimated disï¿¾sociation constant of 18(2) mM, in good agreeï¿¾ment with the CA151/CypA dissociation constant
measured under the same conditions by isothermal
titration microcalorimetry (see Table 1).
Subsequent experiments measured CypA bindï¿¾ing to the intact capsid protein. In this case, the
GST-CA fusion protein was captured directly from
the soluble fraction of crude E. coli extracts followï¿¾ing induction of protein expression. Capture of
GST-CA directly onto the sensor surface was
highly speciÂ®c, since non-speciÂ®c protein binding
in control extracts lacking GST-CA was negligible
(not shown). CypA dissociation constants were
again obtained by Â®tting binding data (Figure 5(b))
from two different CA surface derivatization levels
to a single-site binding model (Figure 5(c)). Nine
independent repetitions of this experiment yielded
a mean dissociation constant of 15 mM, with a stanï¿¾dard deviation of 5 mM (Table 1). The excellent
agreement between all of the ITC and SPR
measurements validates the SPR method, and
further supports the conclusion that the carboxylï¿¾terminal dimerization domain of HIV-1 CA does
not inÂ¯uence the afÂ®nity of CypA binding.
Figure 5. Surface plasmon resonance analysis of the CA/CypA interaction. (a) Sensorgrams for CA151 binding to a
GST-CypA surface. Binding responses are shown for CA151 injected at concentrations of 57, 19, 6.3 and 2.1 mM. Each
injection was repeated two or three times in random order. (b) Sensorgrams for CypA binding to a GST-CA surface.
Binding responses for CypA injected at 114, 38, 12, 4.2 and 0 mM. (c) Fit of the equilibrium binding data. Binding reï¿¾sponses from the sensor experiments shown in (a) and (b) were separately Â®t to single-site binding models, yielding
estimated dissociation constants of 18(2) mM (CA151) and 18(1) mM (CA). Equilibrium binding levels were deterï¿¾mined by averaging the responses between 10 and 15 seconds after the sample injection. The data and Â®t for the
CA151/GST-CypA interaction are represented by the open circles and continuous line. The data and Â®t for the GSTï¿¾CA/CypA interaction are represented by the Â®lled circles and broken line (the two Â®ts nearly superimpose). Error
bars are drawn at the 90% conÂ®dence interval for clarity.
784 HIV-1 Capsid/Cyclophilin A InteractionImportance of other Gag domains for
CypA binding
Since cyclophilin A is initially packaged by the
HIV-1 Gag polyprotein, we considered the possiï¿¾bility that the amino-terminal matrix or the carï¿¾boxyl-terminal nucleocapsid domains of Gag might
participate in CypA binding. CypA binding to imï¿¾mobilized GST-MA-CA (Gag residues 1 to 363)
and to GST-CA-NC-p6 (Gag residues 133 to 432)
was therefore examined. As shown in Table 1,
measured dissociation constants for CypA bindï¿¾ing were 12(1) mM (MA-CA) and 14(2) mM (CAï¿¾NC). In a parallel control experiment, the
measured dissociation constant for the CA/CypA
complex was 12.0(0.4) mM. We therefore conclude
that the CypA binding afÂ®nity is not signiÂ®cantly
affected by Gag residues outside the central capsid
domain.
Mutational analysis of the cyclophilin A
binding site on HIV-1 CA
The biochemical experiments described above,
together with the CA151/CypA co-crystal structure
(Gamble et al., 1996), indicate that CA/CypA comï¿¾plex formation is mediated entirely by the contiguï¿¾ous capsid loop sequence Pro85 to Pro93 binding
in the active site of cyclophilin A (see Figures 1(c)
and 6(a)). To determine the relative importance of
individual capsid residues in sequence-speciÂ®c cyï¿¾clophilin A binding, each CA binding loop residue
was mutated and the effect of the mutation on
CypA binding energy was measured (Table 2 and
Figure 6(b)). Mutations were made in the context
of the full-length capsid protein, and afÂ®nity bindï¿¾ing measurements were performed by SPR specï¿¾troscopy as described above. To keep the
mutagenesis as unbiased as possible, each CA loop
residue was initially mutated to alanine, except for
Ala88 and Ala92, which were mutated to both Gly
and Val. Additional point mutations were subï¿¾sequently used to test speciÂ®c aspects of CypA recï¿¾ognition. Overall, the mutational analysis revealed
that capsid residues Gly89 and Pro90 are the key
determinants for cyclophilin A recognition, while
the Â¯anking residues Pro85, Val86, His87, Ala88,
Ala92 and Pro93 also make favorable contributions
to the afÂ®nity of the CA/CypA complex. As deï¿¾scribed below in detail, these results are in excelï¿¾lent agreement with the CA151/CypA co-crystal
structure.
The CA151/CypA co-crystal structure indicated
that CA Pro90 should be a major determinant of
CypA binding, because the proline ring is buried
in a deep hydrophobic pocket formed by CypA reï¿¾sidues Phe60, Met61, Phe113 and Leu122. Analoï¿¾gous binding of proline residues has been
observed in a number of cyclophilin A peptide
complexes (Kallen & Walkinshaw, 1992; Ke et al.,
1993; Zhao & Ke, 1996a,b). Detailed examination of
the structure suggested that an Ala90 side-chain
could be accommodated in the CypA binding
pocket, albeit with the loss of favorable binding
interactions at the Pro90 Cg and Cd positions,
whereas any larger side-chain should clash with
the sides of the proline binding pocket. For
example, a b-branched side-chain at CA residue 90
is predicted to clash with the CypA Leu122 sideï¿¾chain. Consistent with this analysis, mutation of
CA Pro90 to Ala reduced the CypA binding afÂ®-
nity by 2.1 kcal/mol, while mutation of Pro90 to
Val resulted in immeasurably low (>3 kcal/mol reï¿¾duced) CypA binding afÂ®nity.
The mutational analyses further revealed that
CA Gly89 is also a major determinant of CypA recï¿¾ognition, since mutation of Gly89 to Ala or Val reï¿¾duced the CypA binding by 2.0 and 2.9 kcal/mol,
respectively. The CA151/CypA co-crystal structure
shows that Gly89 contributes to CypA binding afÂ®-
nity in two different ways. First, Gly89 adopts
phi/psi angles (148/155) that are less favored for
non-glycine residues. Moreover, the lack of a sideï¿¾chain at Gly89 allows this residue to Â®t snugly
against the CypA active site, whereas a b-carbon
atom at this position would exhibit steric clash
with CypA Arg55 NZ2 and Gln63 Od1
. The unusual
torsion angles and tight Â®t of Gly89 in the CypA
active site appear critically important, because they
allow the Gly89-Pro90 peptide bond to adopt an
unprecedented trans conformation. This is in conï¿¾trast to all previously characterized model peptide
complexes with CypA, in which the peptide proï¿¾Table 1. Measured dissociation constants for capsid/
cyclophilin A complexes
Protein interaction
Physical
measurement pH Kd (mM)
CypA/CA ITCa 6.5 16(4)
b
CA151/CypA ITC 6.5 16(3)
GST-CA/CypA SPRc 6.5 15  5d
GST-CypA/CA151 SPR 6.5 18(2)
GST-MA-CA/CypAe SPR 6.5 12(1)
GST-CA-NC-p6/CypAf SPR 6.5 14(2)
GST-CypA/CA151 SPR 5.5 42(2)
GST-CypA/CA151 SPR 6.5 18(2)
GST-CypA/CA151 SPR 7.5 24(1)
GST-CypA/CA151 SPR 8.5 35(2)
a Isothermal titration calorimetry was performed as described
in Materials and Methods. b Numbers in parentheses represent estimated errors of one
standard deviation in the Â®nal digit and were derived from the
Â®ts of a single binding experiment. c Surface plasmon resonance spectroscopy was performed as
described in Materials and Methods. d Value is the average of nine independent measurements
made on different days with different protein preparations. The
error is the standard deviation in the repeated experiments. In
these experiments, the GST-CA protein was afÂ®nity-puriÂ®ed
directly from soluble expression extracts onto an anti-GST
mAb-derivatized sensor chip. Proteins used in all other experiï¿¾ments were puriÂ®ed to homogeneity prior to use in the binding
assays. e GST-MA-CA consists of the GST protein fused to HIV-1
Gag residues 1 to 363. f GST-CA-NC-p6 consists of the GST protein fused to HIV-1
Gag residues 133 to 499. Note that this protein exhibited sevï¿¾eral degradation products in addition to the full-length protein
when puriÂ®ed by glutathione afÂ®nity chromatography and anaï¿¾lyzed by SDS-PAGE.
HIV-1 Capsid/Cyclophilin A Interaction 785line residue was always in the cis conformation
(Kallen & Walkinshaw, 1992; Ke et al., 1993;
Kakalis & Armitage, 1994; Zhao & Ke, 1996a,b).
The trans-Pro90 conformation, in turn, orients the
preceding capsid residues down into the CypA acï¿¾tive site groove, where they make a series of favorï¿¾able contacts (Figure 6(a)). The structure therefore
clearly rationalizes why adding steric bulk to the
Gly89 side-chain is energetically unfavorable.
A third determinant of CypA binding speciÂ®city
is His87, which contributes to CypA binding by
forming a van der Waals interaction (CA His87 Ce
Figure 6. Molecular recognition in the capsid/cyclophilin A complex. (a) Stereoview of HIV-1 capsid protein binding
interactions in the cyclophilin A active site. The CA loop sequence Pro85 to Pro93 (stick bonds) is shown bound in
the active site groove of CypA (space-Â®lling model). Color coding is as follows: CA carbon, white; CypA carbon, yelï¿¾low; oxygen, red; nitrogen, blue; sulfur, green; bound water molecule, pink. Broken lines represent intermolecular
hydrogen bonds. (b) Free energy changes in cyclophilin A binding to mutant HIV-1 capsid proteins. Free energy
changes are shown relative to CypA binding to wild-type CA. Mutated binding site residues are labeled below and
the speciÂ®c point mutations are indicated above. The broken lines above the Pro90 to Val mutation indicate that the
change in free energy of CypA binding is greater than 3.0 kcal/mol for this mutant.
786 HIV-1 Capsid/Cyclophilin A Interactionto CypA Thr73 Cg
) and an intermolecular hydroï¿¾gen bond (CA His87 Nd to CypA Asn71 O) across
the CA/CypA interface. Mutation of His87 to Ala
removes these interactions and decreases the bindï¿¾ing afÂ®nity by 0.9 kcal/mol. The pH-dependence
of the CA/CypA dissociation constant was tested,
since the observed intermolecular hydrogen bondï¿¾ing of His87 Nd suggested that the complex should
be less stable at higher pH. As shown in Table 1,
we Â®nd that the complex stability does exhibit a
measurable pH-dependence and is approximately
twofold more stable at pH 6.5 than at either pH 8.5
or 5.5.
Unlike Pro90 and Gly89, CA His87 is not excepï¿¾tionally conserved in different HIV-1 strains
(Myers et al., 1995). Although the majority (77) of
95 collected HIV-1 sequences have His at capsid
position 87, Gln (17) and Arg (1) are also repï¿¾resented at this position (this analysis excludes the
group O viruses, discussed below). It seemed possï¿¾ible that these rather conservative changes might
retain some of the favorable interactions of His87.
We found, however, that mutation of His87 to Gln
or Arg diminished CypA binding by 0.9 and
1.2 kcal/mol, respectively. This observation
suggests that that the virus may not be under
strong selective pressure to maximize CypA packaï¿¾ging levels (although residue 87 may, of course,
perform additional role(s) in HIV-1 replication that
inÂ¯uence its mutational spectrum).
The CA151/CypA structure exhibits other van
der Waals interactions between CypA and CA
side-chains that could contribute to binding speci-
Â®city. For example, the CA Ala88 methyl group
makes van der Waals interactions with CypA
Gln111, Ala101, Asn102 and Ala103. The CA Ala88
to Gly mutation removes these interactions and deï¿¾creases the CypA binding afÂ®nity by 2.2 kcal/mol.
In contrast, the favorable van der Waals interï¿¾actions at the Cb position are presumably mainï¿¾tained in an Ala88 to Val mutation, since this
mutation reduces CypA binding by only 0.6 kcal/
mol. A similar, but less dramatic effect is seen at
position 92, where the Ala92 methyl group interï¿¾acts with CypA Phe60 and the CA Ala92 to Gly
and Val mutations reduce CypA binding afÂ®nity
by 0.5 and 0.4 kcal/mol, respectively. Finally, the
energetic contributions of other side-chain posï¿¾itions that make van der Waals interactions with
CypA, Pro85 Cd
, Val86 Cg
, and Pro93 Cg
, were
tested with alanine mutations. These mutations reï¿¾duced the CypA binding afÂ®nity by 0.6, 0.6 and
0.3 kcal/mol, respectively. In summary, every
single intermolecular interaction made by a CA
side-chain in the crystal structure of the CA151/
CypA complex was removed by mutagenesis and
found to contribute to CypA binding afÂ®nity in
solution.
Uniquely, mutations at the CA Ile91 residue had
no measurable effect on the energy of CypA bindï¿¾ing. Consistent with this observation, Ile91 is the
only capsid residue in the CypA binding loop
whose side-chain projects directly out of the CypA
active site and makes no intermolecular contact
(see Figure 6(a)). An initial measurement suggested
that the Ile91 to Ala mutation mutation might actuï¿¾ally increase the CypA binding energy slightly, but
this observation proved statistically insigniÂ®cant
(see Table 2). Similarly, a CA Ile91 to Val mutation
had no effect on CypA binding.
Cyclophilin A binding to type O HIV-1
capsid proteins
The group O viruses are apparently unique
amongst HIV-1 strains, in that they package cycloï¿¾philin A, but do not require the protein to replicate
(Braaten et al., 1996b). Moreover, the CypA binding
loop sequences of the group O viruses, while reï¿¾taining the central GlyPro binding dipeptide seï¿¾quence, are otherwise signiÂ®cantly diverged from
the far more prevalent group M viruses. For
example, the residues surrounding the CypA bindï¿¾ing loop in the group O, HIV-1MVP5180 capsid proï¿¾tein (83THPPAMGPLPPGQI96) differs from the
group M consensus sequence (83LHPVHAGï¿¾PIAPGQM96) at seven different positions, Â®ve of
which occur within the CypA binding loop itself. It
was therefore of interest to quantify how tightly
CypA binds to the HIV-1MVP5180 loop sequence.
Table 2. Cyclophilin A binding to mutant HIV-1 capsid
proteins
Capsid mutation
CypA binding
afÂ®nity (Kd; mM)
Fold
decreasea
P85A 75(2)
b 3.0
V86A 64(3) 2.7
H87A 66(2) 4.8
H87Q 62(6) 4.8
H87R 193(13) 8
A88V 44(4) 3.4
A88G 1060(1) 44
G89A 400(30) 31
G89V 2000(850) 154
P90A 470(120) 36
P90V >2000c >150
I91A 18  10d 1.2
I91V 12(2) 1.0
A92G 32(2) 2.3
A92V 22(3) 1.7
P93A 38(1) 1.6
83LHPVHAGPIAPGQM96 to 83THPPAMGPLPPGQI96 42(1) 2.5
All measurements were made by surface plasmon resonance
spectroscopy. GST-CA proteins were afÂ®nity-puriÂ®ed directly
from soluble expression extracts onto anti-GST mAb-derivaï¿¾tized sensor chips. Binding experiments were subsequently perï¿¾formed with pure CypA in the mobile phase. a Fold decrease is the decrease in CypA binding afÂ®nity relaï¿¾tive to a control wild-type GST-CA/CypA binding experiï¿¾ment(s) performed in parallel. Kd measurements for nine
independent control reactions varied over a range of
15(5) mM. b Numbers in parentheses represent estimated errors of one
standard deviation in the Â®nal digit(s) and were derived from
the Â®ts of a single binding experiment. c Binding of CypA to the immobilized GST-CA P90V mutant
was too low to quantify accurately. d Kd for three independent measurements with error given at
one standard deviation.
HIV-1 Capsid/Cyclophilin A Interaction 787This was done by creating and expressing a
chimeric GST-CA protein that contained the
HIV-1MVP5180 binding loop sequence in the context
of an otherwise wild-type GST-CANL4-3 capsid
protein. The chimeric capsid protein was immobiï¿¾lized and cyclophilin A binding was quantiÂ®ed by
SPR spectroscopy as described above.
Although CypA bound somewhat less tightly to
the chimeric capsid protein (Kd Âˆ 42(1) mM,
Table 2) as compared to the wild-type CANL4-3 proï¿¾tein, the increase in dissociation constant was modï¿¾est (2.5-fold). This result demonstrates that
although sequences surrounding the central Glyï¿¾Pro sequence can and do modulate CypA binding,
the cyclophilin A active site can tolerate signiÂ®cant
sequence variability without dramatic loss of bindï¿¾ing afÂ®nity. Indeed, it is even possible that while
some of the changes in the HIV-1MVP5180 binding
loop sequence presumably reduce CypA binding
afÂ®nity (e.g. His87 in HIV-1NL4-3 to Ala87 in HIVï¿¾1MVP5180 capsid), other changes in the loop seï¿¾quence may compensate by actually increasing the
binding energy.
Discussion
Capsid dimerization
Equilibrium sedimentation analyses demonstrate
that the carboxyl-terminal 80 amino acid residues
of the HIV-1 capsid protein (residues 152 to 231)
are essential for full afÂ®nity dimerization. Together
with previous proteolytic mapping and NMR stuï¿¾dies (Gitti et al., 1996), these experiments demonï¿¾strate that the HIV-1 capsid protein is composed of
two domains, an amino-terminal core domain that
binds cyclophilin A, and a carboxyl-terminal asï¿¾sembly domain that mediates the highest afÂ®nity
capsid-capsid interaction. Division of capsid into
two distinct functional domains is supported by
genetic studies that reveal that deleterious muï¿¾tations in the carboxyl-terminal third of the protein
generally prevent Gag assembly and particle reï¿¾lease (Jowett et al., 1992; Hong & Boulanger, 1993;
von Poblotzki et al., 1993; Chazal et al., 1994;
Dorfman et al., 1994; Franke et al., 1994a;
Mammano et al., 1994; Zhao et al., 1994; CarrieÃre
et al., 1995; Reicin et al., 1995; Srinivasakumar et al.,
1995; Zhang et al., 1996). In contrast, deleterious
mutations in the amino-terminal two-thirds of capï¿¾sid typically give rise to assembled, but non-infecï¿¾tious virions that frequently fail to form the mature
capsid core structure (Wang & Barklis, 1993;
Dorfman et al., 1994; Reicin et al., 1995).
Two different co-crystal structures of HIV-1 capï¿¾sid proteins bound to other proteins have recently
been reported (Gamble et al., 1996; Momany et al.,
1996). In the structure of CA151 bound to CypA
(Gamble et al., 1996), the capsid fragment is missï¿¾ing residues 152 to 231 and therefore cannot reconï¿¾stitute the entire dimer interface formed by the
intact capsid protein. Consistent with this model,
we have recently crystallized and determined the
structure of the carboxyl-terminal domain of capsid
(CA151-231; unpublished results). As expected,
CA151-231 forms a dimer.
The crystal structure of full-length HIV-1 CA in
complex with an anti-CA Fab fragment has been
reported (Momany et al., 1996). In this structure,
the carboxyl-terminal domains of adjacent CA molï¿¾ecules are distant from one another and lack de-
Â®ned electron density. We therefore conclude that
antibody binding has disrupted the high-afÂ®nity
CA-CA interface formed between the carboxylï¿¾terminal domains, and that this crystal lattice is
dominated by Fab packing interactions. This inï¿¾terpretation is consistent with the fact that identical
crystalline lattices form in both the presence and
absence of the capsid protein.
Viral packaging of cyclophilin A
Our binding measurements have revealed the
stoichiometry and thermodynamics of the cycloï¿¾philin A/capsid interaction. Formation of the CA/
CypA complex is enthalpically driven, with a disï¿¾sociation constant, Kd, of 16 mM. Although cycloï¿¾philin A is initially packaged by the intact Gag
polyprotein, fusing the capsid domain to either the
amino-terminal matrix domain or the carboxylï¿¾terminal NC and p6 domains has no effect on
CypA binding afÂ®nity. The simplest interpretation
of these data is that the capsid domain alone medï¿¾iates CypA binding (although the experiments do
not formally rule out the possibility that CypA
binding could somehow be modulated by contacts
created in the assembled Gag particle that are not
mimicked in our fusion proteins).
The micromolar dissociation constant observed
for the CA/CypA complex suggests that simple
mass action may determine the substoichiometric
level of viral CypA packaging. Given a Kd for the
CA/CypA complex of 16 mM, the 10:1 ratio of
capsid to cyclophilin A in the HIV-1 virion would
be achieved at a free cytoplasmic cyclophilin A
protein concentration of 1.6 mM. Although intraï¿¾cellular levels of cyclophilin A have not been quanï¿¾tiÂ®ed precisely, a micromolar CypA concentration
appears reasonable, since the protein is highly
abundant (Koletsky et al., 1986) and approximately
3 mM concentrations of cyclosporine or its anaï¿¾logues are required to achieve full stoichiometric
inhibition (Franke et al., 1994a; Thali et al., 1994).
Our experiments demonstrate that capsid dimerï¿¾ization and cyclophilin A binding are thermodynaï¿¾mically independent. This conclusion contradicts a
recent report that Gag (or capsid) dimerization is
required for CypA binding (Colgan et al., 1996). A
possible explanation for this discrepancy is that the
previous investigations examined capsid binding
to immobilized GST-CypA. In this conÂ®guration,
dimerization of Gag (or capsid) molecules would
increase the apparent cyclophilin binding afÂ®nity if
the capsid dimers bound bivalently to immobilized
CypA (the chelate effect). In contrast, our microcaï¿¾lorimetry experiments were performed in solution
788 HIV-1 Capsid/Cyclophilin A Interactionand are therefore not subject to the chelate effect.
Importantly, our experiments are likely to reÂ¯ect
the biological situation in which soluble, monoï¿¾meric CypA molecules bind to the assembling Gag
molecules.
The observation that CA dimerization and cycloï¿¾philin A binding are independent agrees well with
the CA151/CypA co-crystal structure. CypA binds
CA151 30 AÃŠ away from the C-terminal dimerizaï¿¾tion domain and it is therefore difÂ®cult to rationalï¿¾ize how cyclophilin A binding could directly affect
formation of the primary capsid dimer interface.
Moreover, there is no signiÂ®cant CypA-CypA
interaction in the co-crystal structure that would
account for cooperative binding of CypA to the
CA dimer. (Gamble et al., 1996). Taken together, all
of these data indicate that cyclophilin A packaging
is mediated entirely by contacts between the CypA
active site and the exposed capsid loop sequence
spanning residues Pro85 to Pro93.
Molecular recognition in the CA/CypA complex
Our mutational analyses reveal that the cycloï¿¾philin A active site can strongly discriminate beï¿¾tween proline residues in different sequence
contexts. The key to sequence-speciÂ®c binding in
the CA/CypA complex is the presence of a glycine
residue (Gly89) preceding the target proline resiï¿¾due (Pro90). Glycine apparently allows the CypA
active site to accommodate the CA Pro90 peptide
bond in a trans conformation, thereby directing the
capsid target sequence to form a series of favorable
interactions along the CypA active site cleft. Hence
it appears that the Gly-Pro dipeptide, rather than
proline alone, forms the fundamental recognition
site for cyclophilin A. The importance of this recogï¿¾nition motif for HIV-1 replication has been demonï¿¾strated by Luban and co-workers, who have
shown that mutation of either Gly89 or Pro90 to
Ala blocks both cyclophilin A packaging and viral
replication (Franke et al., 1994b; Braaten et al.,
1996a). Our mutational analyses demonstrate that
sequences Â¯anking the Gly-Pro binding motif can
also contribute signiÂ®cantly to CypA recognition.
For example, we Â®nd that the CA Ala88 to Gly
mutation decreases the CypA binding afÂ®nity
more than 44-fold, and might also be expected to
inhibit viral packaging of cyclophilin A and block
HIV-1 replication.
Cyclophilin A and HIV-1 replication
Although the precise role of cyclophilin A in
HIV-1 replication remains uncertain, the protein
appears to perform its essential function early in
the viral life-cycle (Steinkasserer et al., 1995;
Braaten et al., 1996a). Luban and co-workers have
reported that CypA-deÂ®cient virions assemble, maï¿¾ture and fuse with their target cells normally, but
that the virus fails to initiate reverse transcription
(Braaten et al., 1996a). This does not seem to reÂ¯ect
a direct effect of CypA on reverse transcriptase,
since the endogenous reverse transcription activity
in detergent-permeabilized, CypA-deÂ®cient virions
is normal (Braaten et al., 1996a). Instead, genetic
analyses indicate that the capsid is both the CypA
binding partner and the functional target of CypA
(Aberham et al., 1996; Braaten et al., 1996a;
Dorfman & GoÃˆttlinger, 1996). These observations
lead to the hypothesis that cyclophilin A may act
to facilitate rearrangement or uncoating of the capï¿¾sid core structure upon infection.
Although cyclophilin A binding does not affect
formation of the highest afÂ®nity CA dimer interï¿¾face, CypA could still affect higher order capsid asï¿¾sembly or disassembly by altering one of the other,
lower afÂ®nity CA-CA interfaces involving the
amino-terminal capsid domain. In the CA151/
CypA co-crystal structure, CA151 molecules associï¿¾ate via two distinct interfaces to form long planar
strips. We envision that the surface of the viral capï¿¾sid core could assemble by side to side packing of
these capsid strips. In the crystal, close packing of
the capsid strips is prevented by stoichiometric
binding of cyclophilin A molecules along the outer
edges of the strips. In the virion, however, the subï¿¾stoichiometric levels of CypA could simply serve
to destabilize the cooperative interactions between
associated capsid strips. Thus, we hypothesize that
the function of cyclophilin A in HIV-1 replication
may be to weaken the capsid core and thereby proï¿¾mote its dissociation upon infection.
Other cyclophilins
Our studies demonstrate that the CypA active
site binds speciÂ®cally to the HIV-1 capsid protein,
providing the Â®rst well-characterized biological
function for a cyclophilin active site. This obserï¿¾vation again raises the possibility, Â®rst suggested
by Schreiber & Crabtree (1992), that proline isoï¿¾merization may not be the primary function of cyï¿¾clophilins in vivo. As has been pointed out by
Harrison & Stein (1990), the modest kc/KM for cyï¿¾clophilin A binding to small model peptides
suggests that rate enhancements for non-speciÂ®c
proline isomerization will be quite modest at
physiological CypA concentrations. Instead, it apï¿¾pears that other cyclophilins may function in anaï¿¾logy to the model that we propose for CypA in
HIV-1, i.e. by binding target proteins with some
level of sequence discrimination and functioning
by modulating or preventing protein-protein interï¿¾actions. This model does not, of course rule out the
possibility that proline isomerase activity may also
be important in vivo.
Since the cyclophilin active site is largely conï¿¾served in eukaryotic cyclophilins (Stamnes et al.,
1992), we speculate that Gly-Pro dipeptides will
form the basic recognition motif for other cyclophiï¿¾lins. We envisage that different cyclophilins may
discriminate between their target proteins by makï¿¾HIV-1 Capsid/Cyclophilin A Interaction 789ing complementary interactions with sequences
Â¯anking the Gly-Pro recognition element. The Glyï¿¾Pro motif forms a convenient binding ``handle'',
since this particular dipeptide is very likely to reï¿¾side in an exposed loop in a folded target protein.
Indeed, since Gly-Pro sequences are likely to end
up in exposed loops and not in integral secondary
structures, it even seems possible that some cycloï¿¾philins may act as chaperones by transiently asï¿¾sociating with the Gly-Pro sequences of folding
proteins and promoting their intramolecular foldï¿¾ing by shielding one face of the unfolded protein
against intermolecular aggregation.
In summary, we have demonstrated that the cyï¿¾clophilin A active site mediates sequence-speciÂ®c
binding of the HIV-1 capsid protein, recognizing
an exposed capsid loop sequence that spans resiï¿¾dues Pro85 to Pro93. The capsid dipeptide, Gly89-
Pro90, forms the core recognition motif, with adjaï¿¾cent residues making a series of additional energeï¿¾tically signiÂ®cant interactions along the CypA
active site groove. We speculate that the HIV-1
CA/CypA interaction may serve as a paradigm for
sequence-speciÂ®c protein recognition within the cyï¿¾clophilin family, with Gly-Pro forming a general
cyclophilin recognition motif.
Materials and Methods
HIV-1 capsid protein expression and purification
Procedures used to express and purify the intact (CA)
and truncated (CA151) capsid proteins were similar and
are therefore described in detail only for the full-length
protein. The HIV-1NL4-3 capsid gene was ampliÂ®ed from
proviral pNL4-3 DNA (Adachi et al., 1986; Myers et al.,
1995) using the polymerase chain reaction (PCR). PCR
primers were designed to introduce NdeI and BamHI
cloning sites, a stop codon, and optimized E. coli codons
for the Â®rst three amino acid residues (Sambrook et al.,
1989). The ampliÂ®ed gene was subcloned into the phage
T7 RNA polymerase-based expression vector, pET3a
(Studier et al., 1990) and the resulting plasmid (WISP93-
73) was conÂ®rmed by DNA sequencing. The expression
vector for the truncated CA151 protein (WISP95-69) was
constructed by introducing oligonuclotides encoding a
stop codon immediately following CA amino acid codon
151 and subcloning the coding region into pET11a.
Protein expression levels and fully puriÂ®ed samples of
the HIV-1 capsid and CA151 proteins are shown in
Figure 2(a) and (b), respectively. BL21 (DE3) E. coli cells
harboring the expression plasmids were grown in LB
medium and capsid protein expression was induced late
in log-phase growth (A600 0.8; lane 1) by the addition
of isoproyl-b,D-thiogalactopyranoside (IPTG) to a Â®nal
concentration of 0.4 mM (1 mM for the pET11a exï¿¾pression constructs). Soluble capsid protein accumulated
to very high levels during the four hour incubation
period (Figure 2(a), lane 2). All steps in the protein puri-
Â®cation were performed at 4C. The cells were lysed in a
French press and the supernatant sonicated to reduce
viscosity. Insoluble material was removed by centrifuï¿¾gation at 40,000 g for one hour and the CA protein was
concentrated by precipitation from 20% saturated amï¿¾monium sulfate. CA was redissolved in a buffer of
25 mM KMops (pH 6.9)/5 mM b-mercaptoethanol and
puriÂ®ed by cation-exchange chromatography on Sï¿¾Sepharose (Pharmacia). The protein eluted at 300 mM
NaCl during a 250 ml 0 to 1 M linear salt gradient. This
procedure typically yielded >30 mg of pure capsid proï¿¾tein per liter of E. coli culture. The recombinant protein
was characterized by N-terminal amino acid sequencing
(NH3-P-I-V), amino acid analysis, and electrospray mass
spectrometry (McalcÂˆ25,603 g/mol, MobsÂˆ25,602(2) g/
mol). A non-native N-terminal methionine residue was
quantitatively (>97%) removed during protein exï¿¾pression and the primary sequence of the puriÂ®ed reï¿¾combinant protein was therefore identical with the
authentic HIV-1 capsid protein. The protein exhibits a
single major isoform in isoelectric focusing experiments
(pI Âˆ 7.05). CA151 was also processed during expression
to produce a native N terminus, as analyzed by N-termï¿¾inal amino acid sequencing and mass spectrometry
(Mcalc Âˆ 16,701 g/mol, Mobs Âˆ 16,700(4) g/mol).
DNA encoding HIV-1NL4-3 CA (encoding Gag resiï¿¾dues 133 to 363), MA-CA (1 to 363), and CA-NC (133
to 499) was also subcloned into a pGEX2T (Pharmacia)
vector that was modiÂ®ed to contain an in-frame NdeI
restriction site immediately downstream of the glutaï¿¾thione-S-transferase gene (WISP94-18). The CA conï¿¾struct was subsequently used as a template for PCRï¿¾based or Muta-Gene Phagemid (Biorad) mutagenesis
(Kunkel et al., 1987), to produce the 17 mutant capsid
proteins used to examine the determinants of CypA
binding speciÂ®city.
Human cyclophilin A expression and purification
The human CypA gene was ampliÂ®ed in a PCR from
a HeLa cDNA pool (Stratagene). The ampliÂ®ed DNA
fragment was subcloned into the NdeI/BamHI sites of
pET3a (Studier et al., 1990) to create WISP94-1 (encoding
native CypA) and into the same sites in WISP94-18 to
create WISP94-57 (encoding GST-CypA). The cloned
human CypA genes were sequenced and corresponded
exactly to the published cDNA sequence of human T-cell
CypA (Haendler et al., 1987).
The induction and puriÂ®cation of recombinant CypA
is shown in Figure 2(c). CypA expression was induced
late in log phase (lane 1) and the protein was allowed to
accumulate for four hours (lane 2). Soluble human CypA
was puriÂ®ed to homogeneity by sequential ammonium
sulfate fractionation, cation-exchange and hydrophobic
chromatographies following a published procedure (Liu
et al., 1990). The puriÂ®ed protein was isolated in reasonï¿¾able yields (typically 25 mg/l cells) and was characterï¿¾ized by N-terminal amino acid sequencing (NH3-
(M)VNP), amino acid analysis, and mass spectrometry
(Mcalc Âˆ 18,013 g/mol; Mobs Âˆ 18,012(1) g/mol). Apï¿¾proximately 15% of the protein molecules were missing
their N-terminal methionine residue (M Âˆ 17,881(1) g/
mol), in good agreement with a previous report (Liu
et al., 1990).
The GST-CypA fusion protein produced from the exï¿¾pression vector WISP94-57 was puriÂ®ed by glutathione
afÂ®nity chromatography on G-Sepharose (Pharmacia).
The protein eluted at a glutathione concentration of
6 mM from a linear gradient of 0 to 10 mM glutathione
in 100 ml of 50 mM Tris-HCl (pH 8.0). The protein was
subsequently dialyzed extensively to remove bound gluï¿¾tathione and puriÂ®ed to homogeneity by cation-exchange
chromatography on S-Sepharose (Pharmacia). The proï¿¾tein eluted at 400 mM NaCl from a linear gradient of 0
790 HIV-1 Capsid/Cyclophilin A Interactionto 1 M NaCl in 250 ml of 25 mM KMops (pH 6.9), 5 mM
b-mercaptoethanol).
Dynamic light-scattering spectroscopy
Dynamic light-scattering was performed to determine
the oligomeric states of the CA and CA151 proteins using
a Dynapro-801 light-scattering instrument (Protein Solï¿¾utions Inc.). Proteins were dissolved in 10 mM potassium
phosphate (pH 6.5), 2 mM b-mercaptoethanol at concenï¿¾trations of 200 mM CA and 158 mM CA151. At least eight
measurements were made and averaged for each sample.
Protein molecular masses were estimated by assuming
globular protein structures and errors are reported as the
standard deviation between the independent measureï¿¾ments.
Equilibrium sedimentation
Analytical ultracentrifugation was used to quantify
the oligomerization of CA and CA151. Centrifugation exï¿¾periments were performed on a Beckman Optima XL-A
ultracentrifuge operating at rotor speeds of 20,000 (CA)
or 25,000 (CA151) rpm. The proteins were centrifuged at
20C in 25 mM sodium phosphate (pH 6.5), 100 mM
NaCl, 2 mM b-mercaptoethanol. Absorbance proÂ®les
were measured at 280 nm and were collected every four
hours until protein distributions had reached equiliï¿¾brium. After 24 hours, eight scans along the cell radius
were collected with a step size of 0.003 cm, averaged,
and corrected for background absorbance against a bufï¿¾fer blank.
Equilibrium distributions were Â®t to the single homoï¿¾geneous species model or to a monomer-dimer model as
described (McRorie & Voelker, 1993), using the Microcaï¿¾lorigin non-linear least-squares Â®tting algorithm proï¿¾vided within the XL-A data analysis software. A solvent
density of 1.0052 g mlÃ¿1 was used and partial speciÂ®c voï¿¾lume estimates of 0.737 ml gÃ¿1 (CA) and 0.740 ml gÃ¿1
(CA151) were derived from the amino acid compositions
of the two proteins (Laue et al., 1992).
Titration calorimetry
Isothermal titration calorimetry (ITC) was performed
at 20.0C using a MicroCal Omega titration calorimeter.
Two different titrations were performed: (1) 632 mM
CA151 was titrated into 59 mM CypA; and (2) 661 mM
CypA was titrated into 59 mM CA. Each titration conï¿¾sisted of 15 injections of 20 ml, made every Â®ve minutes,
into a reaction cell volume of 1.296 ml. All proteins were
dissolved in buffered solutions of 100 mM KCl, 25 mM
KPO4 (pH 6.5), 5 mM b-mercaptoethanol. Reaction heats
were baseline-corrected manually using the Origin TC
software, corrected by subtraction of the appropriate
blank titrations, and integrated. Thermodynamic parï¿¾ameters for the binding reactions were derived by Â®tting
the corrected binding isotherms to single-site binding
models as described (Wiseman et al., 1989), with stoichiï¿¾ometries (n), enthalpies (H), and equilibrium disï¿¾sociation constants (Kd) allowed to Â¯oat during nonï¿¾linear least-squares Â®ts of the data. Titrations were perï¿¾formed under conditions where the product of the bindï¿¾ing constant and the reservoir macromolecule
concentration (c) was approximately 4, and can therefore
be expected to provide reasonable estimates of the bindï¿¾ing equilibria.
Surface plasmon resonance measurements
SPR measurements were performed on a BIACORE
2000 biosensor, with CM5 research-grade chips, NHS/
EDC coupling reagents, ethanolamine, anti-GST monoï¿¾clonal antibody and P20 from Biacore AB (Uppsala, Sweï¿¾den). The binding assays were performed by capturing
either GST-CypA or GST-CA onto the chip surfaces and
measuring the interaction with either CA151 or CypA in
solution. A monoclonal antibody against GST (anti-GST)
was immobilized on the sensor surface using a standard
amine coupling procedure (LoÃˆfaÃŠ s & Johnsson, 1990). The
carboxymethyl dextran surface was activated with a
seven minute injection of a mixture of NHS/EDC (each
at 0.1 M in water). The antibody was immobilized at the
same level (5000 RU) on different Â¯ow-cells by exposï¿¾ing the activated surfaces to a 10 mg/ml sample in
10 mM sodium acetate (pH 5.0) for 300 seconds. After
the coupling step, the remaining activated groups were
blocked with a seven minute wash of 1 M ethanolamine
(pH 8.2), followed by several ten second washes with
glycine (pH 2.0) to remove non-covalently bound
protein.
All subsequent binding experiments were performed
in buffer containing 100 mM sodium chloride, 25 mM
potassium phosphate (pH 6.5), 1 mM b-mercaptoethanol,
and 0.005% (v/v) P20 at pH 6.5, unless otherwise indiï¿¾cated. PuriÂ®ed GST-CypA was captured onto anti-GST
surfaces at two different densities by injecting superï¿¾natant containing GST-CypA for varying lengths of time
at a Â¯ow-rate of 5 ml/minute. Equal quantities of recomï¿¾binant GST alone were captured onto control surfaces.
To perform the kinetic measurements for CA151 binding,
the Â¯ow-path was changed to include all four Â¯ow-cells
and the Â¯ow-rate was increased to 50 ml/minute: 22 ml of
CA151 at concentrations of 57, 19, 6.3 and 2.1 mM along
with a buffer blank were injected over all four Â¯ow-cells
in series. Since the response returned rapidly to baseline,
no regeneration step was required between CA151 injecï¿¾tions. Each binding experiment was repeated two or
three times in random order. Analogous experiments
were performed at pH 5.5, 7.5 and 8.5.
Similar binding experiments were performed for the
GST-CA constructs by capturing these proteins onto the
sensor surface and monitoring the interaction with CypA
in solution. In this case, native and mutant GST-CA proï¿¾teins were captured directly from crude E. coli superï¿¾natants. To examine CypA binding, 30 ml of CypA
solution was injected at concentrations of 114, 38, 12 and
4.2 mM, along with a buffer blank. Each CypA injection
was repeated three times in random order over two
different densities of GST-CA. Control experiments were
performed using a recombinant GST to ensure that
CypA did not interact with this protein or the anti-GST
antibody on the sensor surface.
To analyze the interactions recorded on the biosenï¿¾sor, the raw response data collected from the individï¿¾ual Â¯ow-cells were baseline-corrected by subtracting
the average of the response over 60 seconds prior to
sample injection. To correct for refractive index
change and non-speciÂ®c binding, the response colï¿¾lected over a blank surface was subtracted from the
Â¯ow-cell containing the GST-fusion protein. The reï¿¾sponse at equilibrium, which represents the level of
CA/CypA complex formation, was determined by
averaging the signal obtained over Â®ve to ten seconds
after the start of the injection. Equilibrium dissociation
constants (Kd) for each interaction were determined
from non-linear least-squares curve Â®tting of the data
HIV-1 Capsid/Cyclophilin A Interaction 791to a single-site binding model as described in the
BIACORE manual.
Acknowledgements
This work was supported by NIH grant RO1 AI40333
(to C.P.H. and W.I.S.) and by the Lucille P. Markey
Charitable Trust. We thank Lin Roden for technical asï¿¾sistance with the SPR measurements, Theresa Gamble
and Allyson Christensen for help with Figures, and Jerï¿¾emy Luban for helpful discussions and for communicatï¿¾ing work prior to publication.
References
Aberham, C., Weber, S. & Phares, W. (1996). Sponï¿¾taneous mutations in the human immunodeÂ®ciency
virus type 1 gag gene that affect viral replication in
the presence of cyclosporins. J. Virol. 70, 3536Â±3544.
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T.,
Willey, R., Rabson, A. & Martin, M. A. (1986). Proï¿¾duction of acquired immunodeÂ®ciency syndromeï¿¾associated retrovirus in human and nonhuman cells
transfected with an infectious molecular clone.
J. Virol. 59, 284Â±291.
Anderson, S. K., Gallinger, S., Roder, J., Frey, J., Young,
H. A. & Ortaldo, J. R. (1993). A cyclophilin-related
protein involved in the function of natural killer
cells. Proc. Natl Acad. Sci. USA, 90, 542Â±546.
Baker, E. K., Colley, N. J. & Zuker, C. S. (1994). The
cyclophilin homolog NinaA functions as a chaperï¿¾one, forming a stable complex in vivo with its proï¿¾tein target rhodopsin. EMBO J. 13, 4886Â±4895.
Billich, A., Hammerschmid, F., Peichl, P., Wenger, R.,
Zenke, G., Quesniaux, V. & Rosenwirth, B. (1995).
Mode of action of SDZ NIM 811, a nonimmunosupï¿¾pressive cyclosporin A analog with activity against
human immunodeÂ®ciency virus (HIV) type 1: interï¿¾ference with HIV protein-cyclophilin A interactions.
J. Virol. 69, 2451Â±2461.
Braaten, D., Franke, E. K. & Luban, J. (1996a). Cyclophiï¿¾lin A is required for an early step in the life cycle of
human immunodeÂ®ciency virus type I before the inï¿¾itiation of reverse transcription. J. Virol. 70, 3551Â±
3560.
Braaten, D., Franke, E. K. & Luban, J. (1996b). Cyclophiï¿¾lin A is required for the replication of group M
human immunodeÂ®ciency virus type 1 (HIV-1) and
simian immunodeÂ®ciency virus SIVCPZGAB but not
group O HIV-1 or other primate lentiviruses. J. Virol.
70, 4220Â±4227.
Braaten, D., Aberham, C., Franke, E. K., Yin, L., Phares,
W. & Luban, J. (1996c). Cyclosporin A-resistant
human immunodeÂ®ciency virus type 1 mutants
demonstrate that Gag encodes the functional target
of cyclophilin A. J. Virol. 70, 5170Â±5176.
Bram, R. J. & Crabtree, G. R. (1994). Calcium signalling
in T cells stimulated by a cyclophilin B-binding
protein. Nature, 371, 355Â±358.
Brandts, J. F., Halvorson, H. R. & Brennan, M. (1975).
Consideration of the possibility that the slow step
in protein denaturation reactions is due to cis-trans
isomerism of proline residues. Biochemistry, 14,
4953Â±4963.
Brandts, J. F., Lin, L.-N., Wiseman, T., Williston, S. &
Yang, C. P. (1990). An instrument for rapid determiï¿¾nation of binding constants for biomolecules. Am.
Lab. (Shelton, Conn), 22, 30Â±36.
Brooks, I., Watts, D. G., Soneson, K. K. & Hensley, P.
(1994). Determining conÂ®dence intervals for parï¿¾ameters derived from analysis of equilibrium anaï¿¾lytical ultracentrifugation data. Methods Enzymol.
240, 459Â±478.
Bundle, D. R. & Sigurskjold, B. W. (1994). Determination
of accurate thermodynamics of binding by titration
microcalorimetry. Methods Enzymol. 247, 288Â±305.
Cardenas, M. E., Hemenway, C., Muir, R. S., Ye, R.,
Fiorentino, D. & Heitman, J. (1994). Immunophilins
interact with calcineurin in the absence of exogenï¿¾ous immunosuppressive ligands. EMBO J. 13,
5944Â±5957.
CarrieÃre, C., Gay, B., Chazal, N., Morin, N. &
Boulanger, P. (1995). Sequence requirements for
encapsidation of deletion mutants and chimeras of
human immunodeÂ®ciency virus type 1 Gag precurï¿¾sor into retrovirus-like particles. J. Virol. 69, 2366Â±
2377.
Chang, H.-C. J. & Lindquist, S. (1994). Conservation of
Hsp90 macromolecular complexes in Saccharomyces
cerevisiae. J. Biol. Chem. 269, 24983Â±24988.
Chazal, N., CarrieÃ‚re, C., Gay, B. & Boulanger, P. (1994).
Phenotypic characterization of insertion mutants of
the human immunodeÂ®ciency virus type 1 Gag preï¿¾cursor expressed in recombinant baculovirusï¿¾infected cells. J. Virol. 68, 111Â±122.
Colgan, J., Yuan, H. E. H., Franke, E. K. & Luban, J.
(1996). Binding of the human immunodeÂ®ciency
virus type 1 Gag polyprotein to cyclophilin A is
mediated by the central region of capsid and
requires Gag dimerization. J. Virol. 70, 4299Â±4310.
Colley, N. J., Baker, E. K., Stamnes, M. A. & Zuker, C. S.
(1991). The cyclophilin homolog ninaA is required
in the secretory pathway. Cell, 67, 255Â±263.
Davis, E. S., Becker, A., Heitman, J., Hall, M. N. &
Brennan, M. B. (1992). A yeast cyclophilin gene
essential for lactate metabolism at high temperature.
Proc. Natl Acad. Sci. USA, 89, 11169Â±11173.
Di Marzo Veronese, F., Copeland, T. D., Oroszlan, S.,
Gallo, R. C. & Sarngadharan, M. G. (1988). Bioï¿¾chemical and immunological analysis of human
immunodeÂ®ciency virus gag gene products p17 and
p24. J. Virol. 62, 795Â±801.
Dorfman, T. & GoÃˆttlinger, H. G. (1996). The human
immunodeÂ®ciency virus type 1 capsid p2 domain
confers sensitivity to the cyclophilin-binding drug
SDZ NIM 811. J. Virol. 70, 5751Â±5757.
Dorfman, T., Bukovsky, A., OÃˆ hagen, AÃŠ ., HoÃˆgland, S. &
GoÃˆttlinger, H. G. (1994). Functional domains of the
capsid protein of human immunodeÂ®ciency virus
type 1. J. Virol. 68, 8180Â±8187.
Duina, A. A., Change, H.-C. J., Marsh, J. A., Lindquist,
S. & Gaber, R. F. (1996). A cyclophilin function in
Hsp90-dependent signal transduction. Science, 274,
1713Â±1715.
Ehrlich, L. S., Agresta, B. E. & Carter, C. A. (1992).
Assembly of recombinant human immunodeÂ®ciency
virus type 1 capsid protein in vitro. J. Virol. 66,
4874Â±4883.
Ehrlich, L. S., Agresta, B. E., Gelfand, C. A., Jentoft, J. &
Carter, C. A. (1994). Spectral analysis and tryptic
susceptibility as probes of HIV-1 capsid protein
structure. Virology, 204, 515Â±525.
Ferreira, P. A., Nakayama, T. A., Pak, W. L. & Travis,
G. H. (1996). Cyclophilin-related protein RanBP2
792 HIV-1 Capsid/Cyclophilin A Interactionacts as a chaperone for red/green opsin. Nature,
383, 637Â±640.
Fischer, G., Wittmann-Liebold, B., Lang, K., Kiefhaber,
T. & Schmid, F. X. (1989). Cyclophilin and peptidylï¿¾prolyl cis-trans isomerase are probably identical
proteins. Nature, 337, 476Â±478.
Fisher, H. F. & Singh, N. (1995). Calorimetric methods
for interpreting protein-ligand interactions. Methods
Enzymol. 259, 194Â±221.
Franke, E. K. & Luban, J. (1995). Cyclophilin and Gag in
HIV-1 replication and pathogenesis. In Cell Actiï¿¾vation and Apoptosis in HIV Infection (Andrieu, A.-
M. & Lu, W., eds), pp. 217Â±228, Plenum Press,
New York.
Franke, E. K., Yuan, H. E. H., Bossolt, K. L., Goff, S. P. &
Luban, J. (1994a). SpeciÂ®city and sequence requireï¿¾ments for interactions between various retroviral
Gag proteins. J. Virol. 68, 5300Â±5303.
Franke, E. K., Yuan, H. E. H. & Luban, J. (1994b).
SpeciÂ®c incorporation of cyclophilin A into HIV-1
virions. Nature, 372, 359Â±362.
Freeman, B. C., Toft, D. O. & Morimoto, R. I. (1996).
Molecular chaperone machines: chaperone activities
of the cyclophilin Cyp-40 and the steroid aporecepï¿¾tor-associated protein p23. Science, 274, 1718Â±1720.
FreskgaÃŠrd, P.-O., Bergenhem, N., Jonsson, B.-H.,
Svensson, M. & Carlsson, U. (1992). Isomerase and
chaperone activity of prolyl isomerase in the folding
of carbonic anhydrase. Science, 258, 466Â±468.
Friedman, J., Trahey, M. & Weissman, I. (1993). Cloning
and characterization of cyclophilin C-associated
protein: a candidate natural cellular ligand for
cyclophilin C. Proc. Natl. Acad. Sci. USA. 90, 6815Â±
6819.
Gamble, T., Vajdos, F., Yoo, S., Worthylake, D.,
Houseweart, M., Sundquist, W. I. & Hill, C. P.
(1996). Crystal structure of human cyclophilin A
bound to the amino-terminal domain of HIV-1
capsid. Cell, 87, 1285Â±1294.
Gelderblom, H. R., Bauer, P. G., OÃˆ zel, M., HoÃˆglund, S.,
Niedrig, M., Renz, H., Morath, B., Lundquist, P.,
Nilsson, AÃŠ ., Mattow, J., Grund, C. & Pauli, G.
(1992). Morphogenesis and morphology of human
immunodeÂ®ciency virus. In Membrane Interactions of
HIV (Aloa, R. C. & Curtain, C. C., eds), pp. 33Â±54,
Wiley-Liss, Inc., New York.
Gitti, R. K., Lee, B. M., Walker, J., Summers, M. F., Yoo,
S. & Sundquist, W. I. (1996). Structure of the aminoï¿¾terminal core domain of the HIV-1 capsid protein.
Science, 273, 231Â±235.
Haendler, B., Hofer-Warbinek, R. & Hofer, E. (1987).
Complementary DNA for human T-cell cyclophilin.
EMBO J. 6, 947Â±950.
Handschumacher, R. E., Harding, M. W., Rice, J. &
Drugge, R. J. (1984). Cyclophilin: a speciÂ®c cytosolic
binding protein for cyclosporin A. Science, 226,
544Â±547.
Harrison, R. K. & Stein, R. L. (1990). Substrate speciÂ®ciï¿¾ties of the peptidyl prolyl cis-trans isomerase activiï¿¾ties of cyclophilin and FK-506 binding protein:
evidence for the existence of a family of distinct
enzymes. Biochemistry, 29, 3813Â±3816.
Helekar, S. A., Char, D., Neff, S. & Patrick, J. (1994).
Prolyl isomerase requirement for the expression of
functional homo-oligomeric ligand-gated ion
channels. Neuron, 12, 179Â±189.
Henderson, L. E., Bowers, M. A., Sowder, R. C., II,
Serabyn, S. A., Johnson, D. G., Bess, J. W., Jr,
Arthur, L. O., Bryant, D. K. & Fenselau, C. (1992).
Gag proteins of the highly replicative MN strain of
human immunodeÂ®ciency virus type 1: posttranslaï¿¾tional modiÂ®cations, proteolytic processings, and
complete amino acid seqences. J. Virol. 66, 1856Â±
1865.
Hong, S. S. & Boulanger, P. (1993). Assembly-defective
point mutants of the human immunodeÂ®ciency
virus type 1 Gag precursor phenotypically
expressed in recombinant baculovirus-infected cells.
J. Virol. 67, 2787Â±2798.
Hunter, E. (1994). Macromolecular interactions in the
assembly of HIV and other retroviruses. Sem. Virol.
5, 71Â±83.
Jackson, S. E. & Ferscht, A. R. (1991). Folding of chymoï¿¾trypsin inhibitor 2. 2. InÂ¯uence of proline isomerizaï¿¾tion on the folding kinetics and thermodynamic
characterization of the transition state of folding.
Biochemistry, 30, 10436Â±10443.
JoÃˆnsson, U., FaÃˆgerstam, L., Ivarsson, B., Johnsson, B.,
Karlsson, R., Lundh, K., LoÃˆfaÃŠ s, S., Persson, B., Roos,
H., RoÃˆnnberg, I., SjoÃˆlander, S., Stenberg, E.,
StaÃŠhlberg, R., Urbaniczky, C., OÃˆ stlin, H. &
Malmqvist, M. (1991). Real-time biospeciÂ®c interï¿¾action analysis using surface plasmon resonance
and a sensor chip technology. BioTechniques, 193,
620Â±627.
Jowett, J., Hockley, D., Nermut, M. V. & Jones, I. M.
(1992). Distinct signals in human immunodeÂ®ciency
virus type 1 Pr55 necessary for RNA binding and
particle formation. J. Gen. Virol. 73, 3079Â±3086.
Kakalis, L. T. & Armitage, I. M. (1994). Solution conforï¿¾mation of a cyclophilin-bound proline isomerase
substrate. Biochemistry, 33, 1495Â±1501.
Kallen, J. & Walkinshaw, M. D. (1992). The X-ray strucï¿¾ture of a tetrapeptide bound to the active site of
human cyclophilin A. FEBS Leters, 300, 286Â±290.
Ke, H. M., Zydowsky, L. D., Liu, J. & Walsh, C. T.
(1991). Crystal structure of recombinant human Tï¿¾cell cyclophilin A at 2.5 AÃŠ resolution. Proc. Natl
Acad. Sci. USA, 88, 9483Â±9487.
Ke, H., Mayrose, D. & Cao, W. (1993). Crystal structure
of cyclophilin A complexed with substrate Ala-Pro
suggests a solvent-assisted mechanism of cis-trans
isomerization. Proc. Natl Acad. Sci. USA, 90, 3324Â±
3328.
Koletsky, A. J., Harding, M. W. & Handschumacher,
R. E. (1986). Cyclophilin: distribution and variant
properties in normal and neoplastic tissues.
J. Immunol. 137, 1054Â±1059.
KraÃˆusslich, H.-G. (1996). Morphogenesis and maturation
of retroviruses. Curr. Topics Microbiol. Immunol. 214.
Kunkel, T. A., Roberts, J. D. & Zakour, R. A. (1987).
Rapid and efÂ®cient site-speciÂ®c mutagenesis withï¿¾out phenotypic selection. Methods Enzymol. 154,
367Â±382.
Kunz, J. & Hall, M. N. (1993). Cyclosporin A, FK506,
and rapamycin: more than just immunosuppression.
Trends Biochem. Sci. 18, 334Â±338.
Laue, T. M., Shah, B. D., Ridgeway, T. M. & Pelletier,
S. L. (1992). Computer-aided interpretation of anaï¿¾lytical sedimentation data for proteins. In Analytical
Ultracentrifugation in Biochemistry and Polymer Science
(Rowe, A. J. & Horton, J. C., eds), pp. 90Â±125,
Royal Society of Chemistry, Cambridge, England.
Lilie, H., Lang, K., Rudolph, R. & Buchner, J. (1993).
Prolyl isomerases catalyze antibody folding in vitro.
Protein Sci. 2, 1490Â±1496.
Liu, J., Albers, M. W., Chen, C.-M., Schreiber, S. L. &
Walsh, C. T. (1990). Cloning, expression, and puriÂ®-
HIV-1 Capsid/Cyclophilin A Interaction 793cation of human cyclophilin in Escherichia coli and
assessment of the catalytic role of cysteines by siteï¿¾directed mutagenesis. Proc. Natl Acad. Sci. USA, 87,
2304Â±2308.
Lodish, H. & Kong, N. (1991). Cyclosporin a inhibits an
initial step in folding of transferrin within the endoï¿¾plasmic reticulum. J. Biol. Chem. 266, 14835Â±14838.
LoÃˆfaÃŠ s, S. & Johnsson, B. (1990). A novel hydrogel matrix
on gold surface plasmon resonance sensors for fast
and efÂ®cient covalent immobilization of ligands.
J. Chem. Soc. Chem. Commun. 21, 1526Â±1528.
Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V. &
Goff, S. P. (1993). Human immunodeÂ®ciency virus
type 1 Gag protein binds to cyclophilins A and B.
Cell, 73, 1067Â±1078.
Malmqvist, M. (1993). Surface plasmon resonance for
detection and measurement of antibody-antigen
afÂ®nity and kinetics. Curr. Opin. Immunol. 5, 282Â±
286.
Mammano, F., OÃˆ hagen, AÃŠ ., HoÃˆglund, S. & GoÃˆttlinger,
H. G. (1994). Role of the major homology region of
HIV-1 in virion morphogenesis. J. Virol. 68, 4927Â±
4936.
McRorie, D. K. & Voelker, P. J. (1993). Self-associating
Systems in the Analytical Ultracentrifuge. Beckman
Instruments Inc., Fullerton, CA.
Momany, C., Kovari, L. C., Prongay, A. J., Keller, W.,
Gitti, R. K., Lee, B. M., Gorbalenya, A. E., Tong, L.,
McClure, J., Ehrlich, L. S., Summers, M. F., Carter,
C. & Rossmann, M. G. (1996). Crystal structure of
dimeric HIV-1 capsid protein. Nature Struct. Biol. 3,
763Â±770.
Morton, T. A., Myszka, D. G. & Chaiken, I. M. (1995).
Interpreting complex binding kinetics from optical
biosensors: a comparison of analysis by linearizaï¿¾tion, the integrated rate equation, and numerical
integration. Anal. Biochem. 227, 176Â±185.
Myers, G., Korber, B., Hahn, B. H., Jeang, K.-T., Mellors,
J. W., McCutchan, F. E., Henderson, L. E. &
Pavlakis, G. N. (1995). Human Retroviruses and AIDS
1995. Los Alamos National Laboratory, Los Alaï¿¾mos, NM.
O'Shannessy, D. J. & Winzor, D. J. (1996). Interpretation
of deviations from pseudo-Â®rst-order kinetic behaï¿¾vior in the characterization of ligand binding by
biosensor technology. Anal. Biochem. 236, 275Â±283.
Ondek, B., Hardy, R. W., Baker, E. K., Stamnes, M. A.,
Shieh, B.-H. & Zuker, C. S. (1992). Genetic dissecï¿¾tion of cyclophilin function. J. Biol. Chem. 267,
16460Â±16466.
Ott, D. E., Coren, L. V., Johnson, D. G., Sowder, R. C. I.,
Arthur, L. O. & Henderson, L. E. (1995). Analysis
and localization of cyclophilin a found in the virï¿¾ions of human immunodeÂ®ciency virus type 1 MN
strain. AIDS Res. Hum. Retro. 11, 1003Â±1006.
Ratajczak, T., Carrello, A., Mark, P. J., Warner, B. J.,
Simpson, R. J., Moritz, R. L. & House, A. K. (1993).
The cyclophilin component of the unactivated estroï¿¾gen receptor contains a tetratricopeptide repeat
domain and shares identity with p59 (FKBP59).
J. Biol. Chem. 268, 13187Â±13192.
Reicin, A. S., Paik, S., Berkowitz, R. D., Luban, J., Lowy,
I. & Goff, S. P. (1995). Linker insertion mutations in
the human immunodeÂ®ciency virus type 1 gag
gene: effects on virion particle assembly, release,
and infectivity. J. Virol. 69, 642Â±650.
RoseÃ‚, S., Hensley, P., O'Shannessy, D. J., Culp, J.,
Debouck, C. & Chaiken, I. (1992). Characterization
of HIV-1 p24 self-association using analytical afÂ®-
nity chromatography. Proteins: Struct. Funct. Genet.
13, 112Â±119.
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecuï¿¾lar Cloning: A Laboratory Manual. 2nd edit., Cold
Spring Harbor Laboratory Press, Plainview, NY.
Schmid, F. X. (1993). Prolyl isomerases: role in protein
folding. Advan. Protein Sci. 44, 25Â±66.
Schmid, R. X. & Baldwin, R. (1978). Acid catalysis of the
formation of the slow folding species of RNase a:
evidence that the reaction is proline isomerization.
Proc. Natl Acad. Sci. USA, 75, 4764Â±4768.
Schneuwly, S., Shortridge, R. D., Larrivee, D. C., Ono,
T., Ozaki, M. & Pak, W. L. (1989). Drosophila ninaA
gene encodes an eye-speciÂ®c cyclophilin (cyclosï¿¾porin A binding protein). Proc. Natl Acad. Sci. USA,
86, 5390Â±5394.
Schreiber, S. L. & Crabtree, G. R. (1992). The mechanism
of action of cyclosporin A and FK506. Immunol.
Today, 13, 136Â±142.
Shieh, B.-H., Stamnes, M. A., Seavello, S., Harris, G. L. &
Zuker, C. S. (1989). The ninaA gene required for
visual transduction in Drosophila encodes a homolï¿¾ogue of cyclosporin A-binding protein. Nature, 338,
67Â±70.
Srinivasakumar, N., HammarskjoÃˆld, M.-L. & Rekosh, D.
(1995). Characterization of deletion mutations in the
capsid region of human immunodeÂ®ciency virus
type 1 that affect particle formation and gag-pol
precursor incorporation. J. Virol. 69, 6106Â±6114.
Stamnes, M. A., Rutherford, S. L. & Zuker, C. S. (1992).
Cyclophilins: a new family of proteins involved in
intracellular folding. Trends Cell Biol. 2, 272Â±276.
Steinkasserer, A., Harrison, R., Billich, A.,
Hammerschmid, F., Werner, G., Wolff, B., Peichl,
P., PalÂ®, G., Schnitzel, W., Mlynar, E. &
Rosenwirth, B. (1995). Mode of action of SDZ NIM
811, a nonimmunosuppressive cyclosporin A analog
with activity against human immunodeÂ®ciency
virus type 1 (HIV-1): interference with early and
late events in HIV-1 replication. J. Virol. 69, 814Â±
824.
Studier, F. W., Rosenberg, A. H., Dunn, J. J. &
Dubendorff, J. W. (1990). Use of T7 RNA polymerï¿¾ase to direct expression of cloned genes. Methods
Enzymol. 185, 60Â±89.
Sykes, K., Gething, M.-J. & Sambrook, J. (1993). Proline
isomerases function during heat shock. Proc. Natl
Acad. Sci. USA, 90, 5853Â±5857.
Takahashi, N., Hayano, T. & Suzuki, M. (1989). Peptiï¿¾dyl-prolyl cis-trans isomerase is the cyclosporin Aï¿¾binding protein cyclophilin. Nature, 337, 473Â±475.
Thali, M., Bukovsky, A., Kondo, E., Rosenwirth, B.,
Walsh, C. T., Sodroski, J. & GoÃˆttlinger, H. G. (1994).
Functional association of cyclophilin A with HIV-1
virions. Nature, 372, 363Â±365.
von Poblotzki, A., Wagner, R., Niedrig, M., Wanner, G.,
Wolf, H. & Modrow, S. (1993). IdentiÂ®cation of a
region in the Pr55 gag polyprotein essential for
HIV-1 particle formation. Virology, 193, 981Â±985.
Walsh, C. T., Zydowsky, L. D. & McKeon, F. D. (1992).
Cyclosporin A, the cyclophilin class of peptidylproï¿¾lyl isomerases, and blockade of T-cell signal
transduction. J. Biol. Chem. 267, 13115Â±13118.
Wang, C.-T. & Barklis, E. (1993). Assembly, processing,
and infectivity of human immunodeÂ®ciency virus
type 1 Gag mutants. J. Virol. 67, 4264Â±4273.
Weisman, R., Creanor, J. & Fantes, P. (1996). A multiï¿¾copy suppressor of a cell cycle defect in S. pombe
794 HIV-1 Capsid/Cyclophilin A Interactionencodes a heat shock-inducible 40 kDa cyclophilinï¿¾like protein. EMBO J. 15, 447Â±456.
Wills, J. & Craven, R. (1991). Form, function, and use of
retroviral Gag proteins. AIDS, 5, 639Â±654.
Wiseman, T., Williston, S., Brandts, J. F. & Lin, L.-N.
(1989). Rapid measurement of binding constants
and heats of binding using a new titration
calorimeter. Anal. Biochem. 179, 131Â±137.
Xu, Q., Leiva, M. C., Fischkoff, S. A., Handschumacher,
R. E. & Lyttle, C. R. (1992). Leukocyte chemotactic
activity of cyclophilin. J. Biol. Chem. 267, 11968Â±
11971.
Zhang, W.-H., Hockley, D. J., Nermut, M. V.,
Morikawa, Y. & Jones, I. M. (1996). Gag-gag interï¿¾actions in the C-terminal domain of human immuï¿¾nodeÂ®ciency virus type 1 p24 capsid antigen are
essential for Gag particle assembly. J. Gen. Virol.
77, 743Â±751.
Zhao, Y. & Ke, H. (1996a). Crystal structure implies that
cyclophilin predominantly catalyzes the trans to cis
isomerization. Biochemistry, 35, 7356Â±7361.
Zhao, Y. & Ke, H. (1996b). Mechanistic implication of
crystal structures of the cyclophilin-dipeptide
complexes. Biochemistry, 35, 7362Â±7368.
Zhao, Y., Jones, I. M., Hockley, D. J., Nermut, M. V. &
Roy, P. (1994). Complementation of human immuï¿¾nodeÂ®ciency virus (HIV-1) Gag particle formation.
Virology, 199, 403Â±408.
Edited by J. A. Wells
(Received 30 January 1997; received in revised form 24 March 1997; accepted 24 March 1997)
HIV-1 Capsid/Cyclophilin A Interaction 795